About John
Dr. John Anagli is a neuroscientist and inventor with over three decades of experience in biotechnology and clinical innovation, pursuing medical research careers in the hospital, pharmaceutical, biotechnology and academic sectors both in Europe and the United States, leading cross-disciplinary teams in neurotherapeutic and diagnostic development. John is the Founder and CEO of NeuroTheranostics, Inc., where he is developing a nasal spray therapeutic designed to treat traumatic brain injury (TBI) or concussion and TBI-associated neurodegenerative conditions, as well as a novel blood test to detect and monitor the progression of brain damage over time following a TBI. Dr. Anagli’s vision, that is the driving force behind his passion, is to change the TBI treatment paradigm through a unique therapeutic-diagnostic platform with a focus on making a direct positive impact on the cognitive, psychological, and socioeconomic outcomes of society and humanity.
About NeuroTheranostics
NeuroTheranostics, Inc., (NTI), is developing a nasal spray treatment and blood test to address the long-term effects of traumatic brain injury (TBI). Current TBI care is limited to keeping patients stable and relieving brain pressure, with no treatments that help the brain heal or tools to track long-term damage. NTI’s therapy, NTI-101, promotes brain repair when given within hours or days after injury, aiming to prevent lasting cognitive and emotional issues. NTI is also creating a blood test to detect and monitor chronic TBI-related brain disorders.